ClinicalTrials.gg
CompletedNCT00442546Updated Jan 22, 2021Results posted

Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement

A Phase 3 interventional study of pregabalin and pregabalin in Osteoarthritis and Postoperative Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Enrollment
170th of 832
307 · median 100
Started
2007
with 41 others
Phase 3
128 of 1,029
8 open now
Registered
119th of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 170th largest by enrollment of the 832 interventional ones that give a count, is one of 42 that started in 2007, is one of 128 in phase 3, and was the 119th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.

03

Conditions studied

  • Osteoarthritis
  • Postoperative Pain

Keywords

  • opioid
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with osteoarthritis (OA) undergoing elective TKA under regional anesthesia (neuroaxial with or without peripheral nerve block).
  • Subjects able to demonstrate sufficient psychomotor dexterity and cognitive capacity to use Patient Controlled Analgesia/Patient Controlled Epidural Analgesia if used as part of the standard of care.
  • The subject's preoperative health is graded as American Society of Anesthesiology Class 1 to Class 3

Exclusion criteria

Exclusion Criteria:

  • Subjects undergoing revision, unicompartmental, bilateral total knee arthroplasty or subjects with planned second knee total knee arthroplasty at time of present procedure.
  • Subjects with inflammatory arthritides (i.e., rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis); Lyme disease.
  • Subjects with fibromyalgia and or other chronic pain syndromes
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    1

    Drug: pregabalin

  • Experimental
    2

    Drug: pregabalin

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • 150 milligram (mg)/ day (double blind)

  • 300 mg/day (double blind)

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)

    The mBPI-SF is a self administered questionnaire developed to assess pain severity and pain interference with functional activities during a 24-hour period prior to evaluation. For the Worst Pain item of the m-BPI-sf scale (11 point Likert scale; range: 0 \[no pain\] to 10 \[pain as bad as you can imagine\]), subjects were asked to rate their pain by marking an "X" in one of the ten boxes that best described their pain at its worst in the last 24 hours post surgery and at least 12 hours after discontinuation of the peripheral nerve block or neuroaxial block.

    Time frame: 48 hours after surgery

Secondary outcomes

  1. Cumulative Total Amount of Opioids Used During the Entire Hospital Stay

    Total cumulative dose calculated as mg of oral morphine equivalent and included opioids given by any route (patient controlled analgesia \[PCA\] pump, parenteral bolus or oral). Results for daily total not including pregabalin (not an opioid). Statistical model included main effect of treatment group and center. 1 subject at 144 h, 300 mg=non-missing data. Due to small sample size (N=1, 300 mg; N=5, other groups) and large opioid consumption for another subject in same center, least squares mean (300 mg, 144 h) is negative.

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours

  2. Opioids Used Post Discharge

    The amount of opioid use was calculated as mg of oral morphine equivalent and included opioids administered by any route (PCA pump, parenteral bolus, or oral). Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period. This outcome measure does not include pregabalin as it is not an opioid.

    Time frame: Week 2, Week 4, Week 6/Early Termination (ET)

  3. Analgesics Used During the Hospital Stay (Acetylsalicylic Acid, Ketorolac, and Paracetamol)

    Total dose for in-hospital visits was the total dose for the day.

    Time frame: 24 hours, 48 hours, 72 hours

  4. Analgesics Used Post Discharge (Acetylsalicylic Acid [Week 2] and Paracetamol [Weeks 2, 4, and 6]

    Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 2, Week 4, Week 6/ET

  5. Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups

    Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 2, Week 4, Week 6/ET

  6. Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 300 mg Treatment Group

    Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 2, Week 4, Week 6/ET

  7. Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4

    Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 4

  8. Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg Treatment Group at Week 4

    Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 4

  9. Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET

    Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 6/ET

  10. Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg and Placebo Treatment Groups at Week 6/ET

    Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

    Time frame: Week 6/ET

  11. The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the Opioid-Related Symptom Distress Scale (OR-SDS) - Frequency Composite Score

    The OR-SDS was used to assess subject-reported levels of frequency concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom frequency was rated as: 1=rarely, 2=occasionally, 3=frequently, or 4=almost constantly. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible frequency score: 0 (less frequent) to 4 (more frequent).

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET

  12. The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Severity Composite Score

    The OR-SDS was used to assess subject-reported levels of severity concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom severity was rated as: 1=slight, 2=moderate, 3=severe, or 4=very severe. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible severity score: 0 (less severe) to 4 (more severe).

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET

  13. The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Degree of Bother Composite Score

    The OR-SDS was used to assess subject-reported level of degree of bother concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom degree of bother was rated as: 1=not at all, 2=a little bit, 3=somewhat, 4=quite a bit, or 5=very much. Average score for each symptom was calculated by taking the mean of patient-reported score. Total possible degree of bother score: 0 (less degree of bother) to 5 (greater degree of bother).

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET

  14. The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Overall Composite Score

    The OR-SDS assessed subject-reported levels of frequency, severity and degree of bother for 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, retching and vomiting. The overall composite score was the average across frequency, severity, and degree of bother scores. Total possible score: 0 (better) to 4.34 (worse).

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET

  15. Total Clinically Meaningful Event (CME) Score

    CMEs were defined using OR-SDS (assesses subject-reported levels of severity concerning 10 symptoms associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion and retching/vomiting). CME = any symptom rated as severe or very severe, with the exception of confusion. Confusion was defined as a CME if the severity score was at least moderate. Total score = the sum of CMEs across symptoms. Each CME = 1 point. Total CME score ranges from 0 to 9.

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, and Week 6/ET

  16. Pain Interference Index Score as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Pain interference index = average of pain interference question (Q) 5A to 5G. Questions were asked as follows: how, during the past 24 hours, has pain interfered with general activity (Q5A), mood (Q5B), walking ability (Q5C), normal work (outside home and housework) (Q5D), relations with other people (Q5E), sleep (Q5F), enjoyment of life (Q5G). Scale: 0=does not interfere to 10=completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  17. Pain Interference With Relations With People as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  18. Pain Interference With Enjoyment of Life as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  19. Pain Interference With General Activity as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  20. Pain Interference With Mood as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  21. Pain Interference With Walking Ability as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  22. Pain Interference With Normal Work as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  23. Pain Interference With Sleep as Measured by the m-BPI-sf

    m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6

  24. Daily and Weekly Worst Pain During the Hospital Stay and Post Discharge Assessed by the Pain Numerical Rating Scale (NRS)

    Subject rated scale for worst pain over the last 24 hours. Scores ranged from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.

    Time frame: 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, and 192 hours during the hospital stay, Week 2, Week 4, Week 6/ET

  25. Daily and Weekly Average Pain During the Hospital Stay and Post Discharge Assessed by the Pain NRS

    Subject rated scale for average pain intensity over the last 24 hours. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.

    Time frame: 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, and 192 hours during the hospital stay, Week 2, Week 4, Week 6/ET

  26. Current Pain During the Hospital Stay Assessed by the Pain NRS

    Subject rated scale for average pain intensity over the last 24 hours. Pain was assessed using the question "How much pain do you have right now?" Scores range from 0 (no pain) to 10 (most possible pain).

    Time frame: 4, 8, 12, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, 184, and 192 hours during the hospital stay

  27. Pain-Related Sleep Interference Post Surgery

    The NRS-Sleep: subject rated 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]) rating how pain has interfered with sleep during the past 24 hours. Weekly mean scores were calculated post hospital discharge.

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours 120 hours, 144 hours, 168 hours, and 192 hours post-surgery, Week 2, Week 4, Week 6/ET

  28. Change From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery

    VAS-Anxiety was administered to measure pre-operative anxiety. Score: 0 = no anxiety to 100 = worst imaginable anxiety.

    Time frame: Day 1, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours prior to surgery

  29. Timed Up-and-Go (TUG)

    TUG: time taken in seconds to rise from a standard arm chair, walk to a line on the floor 3 meters away, turn, return and sit down again.

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Week 2, Week 4, Week 6/ET

  30. Range of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee

    The degree of active (patient moving the knee) knee flexion and extension tolerated by each subject was recorded. Active ROM in the sitting position was assessed with a goniometer.

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours post surgery, Week 2, Week 4, Week 6/ET

  31. ROM Assessment of the Passive Flexion of the Surgical Knee

    The degree of passive (movement of the knee with the aid of physical therapist or designee) knee flexion and extension tolerated by each subject was recorded. Passive ROM in the sitting position was assessed with a goniometer.

    Time frame: 24 hours, 48 hours, 72 hours, 96 hours, and 120 hours post surgery, Week 2, Week 4, Week 6/ET

  32. Time From End of Surgery to Meet Hospital Discharge Criteria

    The analysis was performed by Kaplan-Meier method with log-rank test.

    Time frame: time from end of surgery up to 192 hours post surgery

  33. Time From End of Surgery to Actual Discharge

    The analysis was performed by Kaplan-Meier method with log-rank test.

    Time frame: time from end of surgery up to 192 hours post surgery

  34. Satisfaction With Current Pain Medication Measured by the Pain Treatment Satisfaction Scale (PTSS)

    Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET

  35. Satisfaction With Medication Characteristics Measured by the PTSS

    Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET

  36. Satisfaction With Medication Efficacy Measured by the PTSS

    Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

    Time frame: Discharge, Week 2, Week 4, Week 6/ET

  37. Overall Satisfaction Measured by the PTSS

    Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

    Time frame: Discharge, Week 2, Week 4, and Week 6/ET

  38. Overall Pain Relief Measured by the PTSS

    Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

    Time frame: Discharge, Week 2, Week 4, and Week 6/ET

  39. Number of Subjects With Global Evaluation of Study Medication Scores

    The Global Evaluation of Study Medication is a subject-administered single item instrument that records the subject's overall impression (global evaluation) of the study medication by asking the following question: how would you rate the study medication you received for pain? The subject chooses based on a scale of 1 (poor), 2 (fair), 3 (good), or 4 (excellent).

    Time frame: Discharge, Week 2, Week 4, and Week 6/ET

  40. Number of Subjects With Persistent Pain Based on 11-Point Verbal Rating Scale (VRS)

    The presence of persistent pain was evaluated on the 11-point VRS. The subject answered the question: how much pain did you experience in the last 24 hours in your operated knee? A zero score of VRS was the only number considered as a "no." Any positive score (1-10) of VRS was consider as "yes."

    Time frame: Month 3, Month 6 (phone call)

  41. Neuropathic Pain Symptom Inventory (NPSI)

    NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.

    Time frame: Month 3, Month 6 (phone call)

07

Results

Posted Aug 18, 2010

Participant flow

Participant flow — Overall Study
MilestonePregabalin (150 Milligrams [mg])Pregabalin (300 mg)Placebo
Started103100104
Received treatment989698
Completed776371
Not completed263733
Withdrew: Adverse event111713
Withdrew: Lost to follow-up121
Withdrew: Other496
Withdrew: Withdrawal by subject557
Withdrew: Randomized but not treated546

Outcome measures

PrimarySubject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)

The mBPI-SF is a self administered questionnaire developed to assess pain severity and pain interference with functional activities during a 24-hour period prior to evaluation. For the Worst Pain item of the m-BPI-sf scale (11 point Likert scale; range: 0 \[no pain\] to 10 \[pain as bad as you can imagine\]), subjects were asked to rate their pain by marking an "X" in one of the ten boxes that best described their pain at its worst in the last 24 hours post surgery and at least 12 hours after discontinuation of the peripheral nerve block or neuroaxial block.

Time frame:
48 hours after surgery
Reported as:
Least squares mean · scores on a scale
Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)7.041 ± 0.2676.740 ± 0.2647.079 ± 0.279
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9185 (A step-down procedure was used for multiple comparisons adjustment. If the difference between the high dose and placebo groups was statistically significant (p\<0.05), then the next step conducted where the low dose group was compared to placebo.) · Mean difference (final values): -0.038 · 95% CI -0.766 to 0.691Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3619 (A step-down procedure was used for multiple comparisons adjustment. If the difference between the high dose and placebo groups was statistically significant (p\<0.05), then the next step conducted where the low dose group was compared to placebo.) · Mean difference (final values): -0.339 · 95% CI -1.070 to 0.392Mean difference (final values) = Least squares mean difference
SecondaryCumulative Total Amount of Opioids Used During the Entire Hospital Stay

Total cumulative dose calculated as mg of oral morphine equivalent and included opioids given by any route (patient controlled analgesia \[PCA\] pump, parenteral bolus or oral). Results for daily total not including pregabalin (not an opioid). Statistical model included main effect of treatment group and center. 1 subject at 144 h, 300 mg=non-missing data. Due to small sample size (N=1, 300 mg; N=5, other groups) and large opioid consumption for another subject in same center, least squares mean (300 mg, 144 h) is negative.

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours
Reported as:
Least squares mean · mg of oral morphine equivalent
Cumulative Total Amount of Opioids Used During the Entire Hospital Stay
mg of oral morphine equivalentPregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=85, 86, 84)151.790 ± 14.210152.306 ± 14.313167.854 ± 14.573
48 hours (n=82, 81, 83)86.402 ± 12.05793.846 ± 12.292122.830 ± 12.304
72 hours (n=60, 60, 60)55.654 ± 9.17548.713 ± 9.42052.895 ± 9.851
96 hours (n=32, 39, 35)31.976 ± 7.92824.758 ± 7.86135.332 ± 8.354
120 hours (n=12, 6, 13)27.520 ± 13.14614.235 ± 17.68427.559 ± 13.306
144 hours (n=5, 1, 5)33.956 ± 12.019-64.544 ± 28.63373.956 ± 16.720
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4091 · Mean difference (final values): -16.065 · 95% CI -54.332 to 22.203Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4234 · Mean difference (final values): -15.548 · 95% CI -53.740 to 22.645Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0284 · Mean difference (final values): -36.428 · 95% CI -68.972 to -3.884Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0816 · Mean difference (final values): -28.985 · 95% CI -61.632 to 3.663Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8147 · Mean difference (final values): 2.759 · 95% CI -20.446 to 25.964Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7187 · Mean difference (final values): -4.182 · 95% CI -27.064 to 18.700Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7416 · Mean difference (final values): -3.356 · 95% CI -23.516 to 16.804Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2577 · Mean difference (final values): -10.574 · 95% CI -29.017 to 7.869Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9982 · Mean difference (final values): -0.039 · 95% CI -36.431 to 36.352Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5552 · Mean difference (final values): -13.325 · 95% CI -59.756 to 33.107Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2032 · Mean difference (final values): -40.000 · 95% CI -118.463 to 38.463Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0348 · Mean difference (final values): -138.500 · 95% CI -258.354 to -18.646Mean difference (final values) = Least squares mean difference
SecondaryOpioids Used Post Discharge

The amount of opioid use was calculated as mg of oral morphine equivalent and included opioids administered by any route (PCA pump, parenteral bolus, or oral). Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period. This outcome measure does not include pregabalin as it is not an opioid.

Time frame:
Week 2, Week 4, Week 6/Early Termination (ET)
Reported as:
Least squares mean · mg of oral morphine equivalent
Opioids Used Post Discharge
mg of oral morphine equivalentPregabalin (150 mg)Pregabalin (300 mg)Placebo
Week 2 (n=41, 40, 36)30.255 ± 3.51527.692 ± 3.53426.119 ± 3.789
Week 4 (n=33, 33, 30)37.130 ± 4.97537.507 ± 4.91134.271 ± 5.274
Week 6/ET (n=24, 28, 22)38.686 ± 6.26135.945 ± 5.88835.036 ± 6.401
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3602 · Mean difference (final values): 4.136 · 95% CI -4.790 to 13.062Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7352 · Mean difference (final values): 1.573 · 95% CI -7.626 to 10.771Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6435 · Mean difference (final values): 2.860 · 95% CI -9.392 to 15.111Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6123 · Mean difference (final values): 3.237 · 95% CI -9.422 to 15.895Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6356 · Mean difference (final values): 3.650 · 95% CI -11.683 to 18.984Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9070 · Mean difference (final values): 0.909 · 95% CI -14.593 to 16.411Mean Difference (Final Values) = Least Squares Mean Difference
SecondaryAnalgesics Used During the Hospital Stay (Acetylsalicylic Acid, Ketorolac, and Paracetamol)

Total dose for in-hospital visits was the total dose for the day.

Time frame:
24 hours, 48 hours, 72 hours
Reported as:
Least squares mean · mg
Analgesics Used During the Hospital Stay (Acetylsalicylic Acid, Ketorolac, and Paracetamol)
mgPregabalin (150 mg)Pregabalin (300 mg)Placebo
Acetylsalicylic Acid, 72 hours (n=3, 1, 1)235.175 ± 61.5311442.025 ± 117.8231425.825 ± 117.823
Ketorolac, 24 hours, (n=1, 4, 3)32.961 ± 57.23053.432 ± 28.61527.189 ± 31.346
Ketorolac, 48 hours, (n=2, 8, 4)20.553 ± 7.97121.863 ± 3.86223.473 ± 5.520
Paracetamol, 24 hours (n=14, 20, 16)1311.246 ± 359.8861363.086 ± 283.8081380.481 ± 309.224
Paracetamol, 48 hours (n=22, 25, 17)1357.030 ± 371.0951368.880 ± 339.5091263.337 ± 443.695
Paracetamol, 72 hours (n=12, 13, 16)446.050 ± 445.588877.916 ± 403.6571128.355 ± 347.457
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0656 · Mean difference (final values): -1190.650 · 95% CI -2754.304 to 373.004Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9277 · Mean difference (final values): 16.200 · 95% CI -1789.352 to 1821.752Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9350 · Mean difference (final values): 5.771 · 95% CI -263.972 to 275.515Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6139 · Mean difference (final values): 26.243 · 95% CI -164.494 to 216.980Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7760 · Mean difference (final values): -2.920 · 95% CI -25.451 to 19.611Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8190 · Mean difference (final values): -1.610 · 95% CI -17.066 to 13.846Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8603 · Mean difference (final values): -69.235 · 95% CI -861.171 to 722.700Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9642 · Mean difference (final values): -17.395 · 95% CI -796.945 to 762.155Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8476 · Mean difference (final values): 93.693 · 95% CI -880.865 to 1068.251Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8185 · Mean difference (final values): 105.543 · 95% CI -813.584 to 1024.670Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1792 · Mean difference (final values): -682.304 · 95% CI -1696.759 to 332.150Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6216 · Mean difference (final values): -250.439 · 95% CI -1278.347 to 777.469Mean Difference (Final Values) = Least Squares Mean Difference
SecondaryAnalgesics Used Post Discharge (Acetylsalicylic Acid [Week 2] and Paracetamol [Weeks 2, 4, and 6]

Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · mg
Analgesics Used Post Discharge (Acetylsalicylic Acid [Week 2] and Paracetamol [Weeks 2, 4, and 6]
mgPregabalin (150 mg)Pregabalin (300 mg)Placebo
Acetylsalicylic Acid, Week 2 (n=6, 1, 2)498.613 ± 130.446797.463 ± 361.189992.613 ± 291.687
Paracetamol, Week 2 (n=7, 13, 7)603.496 ± 232.179665.574 ± 164.777630.787 ± 247.693
Paracetamol, Week 4 (n=5, 12, 6)792.434 ± 412.260779.226 ± 260.034593.498 ± 375.124
Paracetamol, Week 6/ET (n=6, 14, 5)1128.952 ± 290.9931098.840 ± 223.9481385.873 ± 334.859
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1996 · Mean difference (final values): -494.000 · 95% CI -1452.720 to 464.720Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6335 · Mean difference (final values): -195.150 · 95% CI -1369.338 to 979.038Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9290 · Mean difference (final values): -27.291 · 95% CI -657.992 to 603.410Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8937 · Mean difference (final values): 34.787 · 95% CI -501.241 to 570.815Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6912 · Mean difference (final values): 198.937 · 95% CI -847.930 to 1245.804Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6024 · Mean difference (final values): 185.728 · 95% CI -558.248 to 929.704Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5372 · Mean difference (final values): -256.921 · 95% CI -1120.551 to 606.709Mean Difference (Final Values) = Least Squares Mean Difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3948 · Mean difference (final values): -287.032 · 95% CI -982.843 to 408.778Mean Difference (Final Values) = Least Squares Mean Difference
SecondaryAnalgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups

Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · mg
Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups
mgPregabalin (150 mg)Placebo
Analgesics Used Post Discharge (Ibuprofen) for the Pregabalin 150 mg and Placebo Treatment Groups862.350 ± 584.827983.850 ± 1119.858
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9341 · Mean difference (final values): -121.500 · 95% CI -14983.36 to 14740.362Mean Difference (Final Values) = Least Squares Mean Difference
SecondaryAnalgesics Used Post Discharge (Ibuprofen) for the Pregabalin 300 mg Treatment Group

Weeks 2, 4, and 6 total daily doses were calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 2, Week 4, Week 6/ET

No measurements were reported for this outcome.

SecondaryAnalgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4

Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 4
Reported as:
Median · mg
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4
mgPregabalin (150 mg)Placebo
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 4650.000 ± 0.00022.100 (22.100 to 22.100)
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = <0.0001 · Mean difference (final values): 302.900 · 95% CI 302.900 to 302.900Mean Difference (Final Values) = Least Squares Mean Difference
SecondaryAnalgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg Treatment Group at Week 4

Week 4 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 4

No measurements were reported for this outcome.

SecondaryAnalgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET

Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 6/ET
Reported as:
Least squares mean · mg
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET
mgPregabalin (150 mg)
Analgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 150 mg and Placebo Treatment Groups at Week 6/ET513.163 ± 200.647
SecondaryAnalgesics Used Post Discharge (Acetylsalicylic Acid) for the Pregabalin 300 mg and Placebo Treatment Groups at Week 6/ET

Week 6 total daily dose was calculated by adding the cumulative doses during the 2 week period prior to the visit and dividing them by the number of days in the period.

Time frame:
Week 6/ET

No measurements were reported for this outcome.

SecondaryThe Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the Opioid-Related Symptom Distress Scale (OR-SDS) - Frequency Composite Score

The OR-SDS was used to assess subject-reported levels of frequency concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom frequency was rated as: 1=rarely, 2=occasionally, 3=frequently, or 4=almost constantly. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible frequency score: 0 (less frequent) to 4 (more frequent).

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the Opioid-Related Symptom Distress Scale (OR-SDS) - Frequency Composite Score
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=72, 69, 69)0.767 ± 0.0690.808 ± 0.0720.888 ± 0.074
48 hours (n=83, 86, 76)0.782 ± 0.0610.779 ± 0.0600.908 ± 0.063
72 hours (n=81, 77, 73)0.669 ± 0.0640.688 ± 0.0660.726 ± 0.069
96 hours (n=49, 53, 54)0.623 ± 0.0870.656 ± 0.0830.676 ± 0.082
120 hours (n=19, 17, 23)0.427 ± 0.0860.405 ± 0.0870.446 ± 0.087
Discharge (n=86, 85, 81)0.567 ± 0.0560.619 ± 0.0560.664 ± 0.058
Week 2 (n=87, 78, 79)0.535 ± 0.0560.525 ± 0.0580.513 ± 0.059
Week 4 (n=77, 69, 67)0.402 ± 0.0480.415 ± 0.0500.391 ± 0.053
Week 6/ET (n=78, 66, 71)0.249 ± 0.0430.386 ± 0.0470.239 ± 0.047
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1661 · Mean difference (final values): -0.121 · 95% CI -0.293 to 0.051Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3604 · Mean difference (final values): -0.081 · 95% CI -0.254 to 0.093Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1299 · Mean difference (final values): -0.126 · 95% CI -0.290 to 0.037Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1167 · Mean difference (final values): -0.129 · 95% CI -0.290 to 0.032Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5271 · Mean difference (final values): -0.057 · 95% CI -0.234 to 0.120Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6731 · Mean difference (final values): -0.038 · 95% CI -0.215 to 0.139Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5936 · Mean difference (final values): -0.053 · 95% CI -0.247 to 0.142Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8368 · Mean difference (final values): -0.019 · 95% CI -0.206 to 0.167Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8659 · Mean difference (final values): -0.019 · 95% CI -0.242 to 0.204Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7151 · Mean difference (final values): -0.041 · 95% CI -0.266 to 0.184Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2121 · Mean difference (final values): -0.097 · 95% CI -0.249 to 0.056Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5607 · Mean difference (final values): -0.045 · 95% CI -0.197 to 0.107Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7797 · Mean difference (final values): 0.022 · 95% CI -0.130 to 0.173Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8761 · Mean difference (final values): 0.012 · 95% CI -0.143 to 0.167Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8619 · Mean difference (final values): 0.012 · 95% CI -0.121 to 0.144Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7256 · Mean difference (final values): 0.024 · 95% CI -0.111 to 0.159Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8659 · Mean difference (final values): 0.010 · 95% CI -0.110 to 0.131Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0203 · Mean difference (final values): 0.146 · 95% CI 0.023 to 0.270Mean difference (final values) = Least squares mean difference
SecondaryThe Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Severity Composite Score

The OR-SDS was used to assess subject-reported levels of severity concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom severity was rated as: 1=slight, 2=moderate, 3=severe, or 4=very severe. The average score for each symptom was calculated by taking the mean of patient-reported score. Total possible severity score: 0 (less severe) to 4 (more severe).

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Severity Composite Score
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=72, 69, 69)0.579 ± 0.0590.590 ± 0.0610.621 ± 0.062
48 hours (n=83, 86, 77)0.642 ± 0.0510.624 ± 0.0500.695 ± 0.053
72 hours (n=81, 77, 73)0.539 ± 0.0540.534 ± 0.0550.562 ± 0.057
96 hours (n=49, 53, 54)0.509 ± 0.0700.502 ± 0.0670.535 ± 0.066
120 hours (n=19, 17, 23)0.366 ± 0.0660.334 ± 0.0670.391 ± 0.066
Discharge (n=86, 85, 82)0.451 ± 0.0480.495 ± 0.0480.488 ± 0.049
Week 2 (n=87, 78, 79)0.390 ± 0.0430.375 ± 0.0450.364 ± 0.045
Week 4 (n=77, 69, 67)0.269 ± 0.0340.308 ± 0.0360.247 ± 0.037
Week 6/ET (n=78, 66, 71)0.182 ± 0.0340.282 ± 0.0370.175 ± 0.037
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5791 · Mean difference (final values): -0.041 · 95% CI -0.187 to 0.105Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6829 · Mean difference (final values): -0.031 · 95% CI -0.178 to 0.117Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4516 · Mean difference (final values): -0.053 · 95% CI -0.190 to 0.085Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3014 · Mean difference (final values): -0.071 · 95% CI -0.207 to 0.064Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7628 · Mean difference (final values): -0.023 · 95% CI -0.171 to 0.125Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7110 · Mean difference (final values): -0.028 · 95% CI -0.176 to 0.120Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7382 · Mean difference (final values): -0.026 · 95% CI -0.183 to 0.130Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6586 · Mean difference (final values): -0.034 · 95% CI -0.183 to 0.116Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7691 · Mean difference (final values): -0.025 · 95% CI -0.195 to 0.145Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5070 · Mean difference (final values): -0.057 · 95% CI -0.229 to 0.115Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5802 · Mean difference (final values): -0.036 · 95% CI -0.166 to 0.093Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9190 · Mean difference (final values): 0.007 · 95% CI -0.122 to 0.136Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6559 · Mean difference (final values): 0.026 · 95% CI -0.090 to 0.143Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8552 · Mean difference (final values): 0.011 · 95% CI -0.108 to 0.130Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6364 · Mean difference (final values): 0.023 · 95% CI -0.072 to 0.117Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2127 · Mean difference (final values): 0.061 · 95% CI -0.035 to 0.157Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8746 · Mean difference (final values): 0.007 · 95% CI -0.086 to 0.101Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0286 · Mean difference (final values): 0.107 · 95% CI 0.011 to 0.202Mean difference (final values) = Least squares mean difference
SecondaryThe Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Degree of Bother Composite Score

The OR-SDS was used to assess subject-reported level of degree of bother concerning 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, and retching/vomiting. Symptom degree of bother was rated as: 1=not at all, 2=a little bit, 3=somewhat, 4=quite a bit, or 5=very much. Average score for each symptom was calculated by taking the mean of patient-reported score. Total possible degree of bother score: 0 (less degree of bother) to 5 (greater degree of bother).

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Degree of Bother Composite Score
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=72, 69, 69)0.671 ± 0.0810.788 ± 0.0840.836 ± 0.086
48 hours (n=83, 86, 77)0.810 ± 0.0670.769 ± 0.0660.918 ± 0.070
72 hours (n=81, 77, 73)0.686 ± 0.0770.694 ± 0.0800.822 ± 0.083
96 hours (n=49, 53, 54)0.572 ± 0.0960.623 ± 0.0920.703 ± 0.090
120 hours (n=19, 17, 23)0.565 ± 0.1110.439 ± 0.1130.574 ± 0.113
Discharge (n=86, 85, 82)0.575 ± 0.0670.616 ± 0.0670.697 ± 0.069
Week 2 (n=87, 78, 79)0.527 ± 0.0630.506 ± 0.0660.533 ± 0.067
Week 4 (n=77, 69, 67)0.395 ± 0.0530.433 ± 0.0550.354 ± 0.058
Week 6/ET (n=78, 66, 71)0.260 ± 0.0490.401 ± 0.0530.274 ± 0.053
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1078 · Mean difference (final values): -0.165 · 95% CI -0.367 to 0.036Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6406 · Mean difference (final values): -0.048 · 95% CI -0.252 to 0.155Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2404 · Mean difference (final values): -0.108 · 95% CI -0.289 to 0.073Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1005 · Mean difference (final values): -0.149 · 95% CI -0.327 to 0.029Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2109 · Mean difference (final values): -0.136 · 95% CI -0.349 to 0.078Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2399 · Mean difference (final values): -0.128 · 95% CI -0.342 to 0.086Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2272 · Mean difference (final values): -0.131 · 95% CI -0.346 to 0.083Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4417 · Mean difference (final values): -0.080 · 95% CI -0.285 to 0.125Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9502 · Mean difference (final values): -0.009 · 95% CI -0.299 to 0.281Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3550 · Mean difference (final values): -0.135 · 95% CI -0.426 to 0.156Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1888 · Mean difference (final values): -0.122 · 95% CI -0.304 to 0.060Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3774 · Mean difference (final values): -0.081 · 95% CI -0.262 to 0.100Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9452 · Mean difference (final values): -0.006 · 95% CI -0.178 to 0.166Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7663 · Mean difference (final values): -0.026 · 95% CI -0.201 to 0.148Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5777 · Mean difference (final values): 0.041 · 95% CI -0.104 to 0.186Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2916 · Mean difference (final values): 0.079 · 95% CI -0.069 to 0.227Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8389 · Mean difference (final values): -0.014 · 95% CI -0.150 to 0.122Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0734 · Mean difference (final values): 0.127 · 95% CI -0.012 to 0.266Mean difference (final values) = Least squares mean difference
SecondaryThe Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Overall Composite Score

The OR-SDS assessed subject-reported levels of frequency, severity and degree of bother for 10 symptoms known to be associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion, retching and vomiting. The overall composite score was the average across frequency, severity, and degree of bother scores. Total possible score: 0 (better) to 4.34 (worse).

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
The Effect of Pregabalin Compared to Placebo on the Occurrence of Opioid-Related Symptoms as Assessed Using the OR-SDS - Overall Composite Score
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=72, 69, 69)0.669 ± 0.0670.727 ± 0.0690.778 ± 0.071
48 hours (n=83, 86, 77)0.743 ± 0.0560.722 ± 0.0550.838 ± 0.059
72 hours (n=81, 77, 73)0.630 ± 0.0630.637 ± 0.0650.703 ± 0.067
96 hours (n=49, 53, 54)0.567 ± 0.0820.593 ± 0.0790.637 ± 0.077
120 hours (n=19, 17, 23)0.453 ± 0.0840.393 ± 0.0860.471 ± 0.085
Discharge (n=86, 85, 82)0.530 ± 0.0550.575 ± 0.0550.615 ± 0.056
Week 2 (n=87, 78, 79)0.482 ± 0.0520.467 ± 0.0550.469 ± 0.056
Week 4 (n=77, 69, 67)0.354 ± 0.0440.384 ± 0.0460.329 ± 0.048
Week 6/ET (n=78, 66, 71)0.230 ± 0.0410.355 ± 0.0450.229 ± 0.045
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1949 · Mean difference (final values): -0.110 · 95% CI -0.276 to 0.057Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5431 · Mean difference (final values): -0.052 · 95% CI -0.220 to 0.116Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2164 · Mean difference (final values): -0.095 · 95% CI -0.247 to 0.056Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1251 · Mean difference (final values): -0.117 · 95% CI -0.266 to 0.033Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4079 · Mean difference (final values): -0.073 · 95% CI -0.247 to 0.101Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4562 · Mean difference (final values): -0.066 · 95% CI -0.240 to 0.108Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4526 · Mean difference (final values): -0.070 · 95% CI -0.254 to 0.114Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6186 · Mean difference (final values): -0.045 · 95% CI -0.221 to 0.132Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8712 · Mean difference (final values): -0.018 · 95% CI -0.237 to 0.202Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4784 · Mean difference (final values): -0.078 · 95% CI -0.300 to 0.143Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2635 · Mean difference (final values): -0.084 · 95% CI -0.232 to 0.064Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6009 · Mean difference (final values): -0.039 · 95% CI -0.187 to 0.108Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8559 · Mean difference (final values): 0.013 · 95% CI -0.130 to 0.156Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9841 · Mean difference (final values): -0.001 · 95% CI -0.147 to 0.144Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6771 · Mean difference (final values): 0.025 · 95% CI -0.095 to 0.146Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3717 · Mean difference (final values): 0.056 · 95% CI -0.067 to 0.178Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9863 · Mean difference (final values): 0.001 · 95% CI -0.114 to 0.116Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0355 · Mean difference (final values): 0.126 · 95% CI 0.009 to 0.243Mean difference (final values) = Least squares mean difference
SecondaryTotal Clinically Meaningful Event (CME) Score

CMEs were defined using OR-SDS (assesses subject-reported levels of severity concerning 10 symptoms associated with opioid medication usage: fatigue, drowsiness, inability to concentrate, nausea, dizziness, constipation, itching, difficulty with urination, confusion and retching/vomiting). CME = any symptom rated as severe or very severe, with the exception of confusion. Confusion was defined as a CME if the severity score was at least moderate. Total score = the sum of CMEs across symptoms. Each CME = 1 point. Total CME score ranges from 0 to 9.

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Discharge, Week 2, Week 4, and Week 6/ET
Reported as:
Least squares mean · scores on a scale
Total Clinically Meaningful Event (CME) Score
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=72, 69, 69)0.822 ± 0.1610.817 ± 0.1660.772 ± 0.171
48 hours (n=83, 86, 87)0.814 ± 0.1410.834 ± 0.1380.789 ± 0.146
72 hours (n=81, 77, 73)0.647 ± 0.1340.570 ± 0.1380.613 ± 0.144
96 hours (n=49, 53, 54)0.440 ± 0.1730.489 ± 0.1640.284 ± 0.162
120 hours (n=19, 17, 23)0.178 ± 0.0890.350 ± 0.0910.246 ± 0.090
Discharge (n=86, 85, 82)0.429 ± 0.1130.502 ± 0.1140.352 ± 0.117
Week 2 (n=87, 78, 79)0.328 ± 0.0930.311 ± 0.0970.171 ± 0.099
Week 4 (n=77, 69, 67)0.116 ± 0.0590.236 ± 0.0620.032 ± 0.064
Week 6/ET (n=78, 66, 71)0.059 ± 0.0620.260 ± 0.0680.051 ± 0.067
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8071 · Mean difference (final values): 0.049 · 95% CI -0.350 to 0.449Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8282 · Mean difference (final values): 0.044 · 95% CI -0.359 to 0.447Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8972 · Mean difference (final values): 0.025 · 95% CI -0.353 to 0.403Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8159 · Mean difference (final values): 0.044 · 95% CI -0.329 to 0.418Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8577 · Mean difference (final values): 0.034 · 95% CI -0.337 to 0.405Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8158 · Mean difference (final values): -0.044 · 95% CI -0.415 to 0.327Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4243 · Mean difference (final values): 0.156 · 95% CI -0.229 to 0.541Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2742 · Mean difference (final values): 0.205 · 95% CI -0.164 to 0.574Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5569 · Mean difference (final values): -0.069 · 95% CI -0.302 to 0.165Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3762 · Mean difference (final values): 0.103 · 95% CI -0.130 to 0.336Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6203 · Mean difference (final values): 0.077 · 95% CI -0.229 to 0.383Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3343 · Mean difference (final values): 0.150 · 95% CI -0.155 to 0.455Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2213 · Mean difference (final values): 0.157 · 95% CI -0.096 to 0.410Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2863 · Mean difference (final values): 0.140 · 95% CI -0.118 to 0.399Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3050 · Mean difference (final values): 0.084 · 95% CI -0.077 to 0.245Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0155 · Mean difference (final values): 0.204 · 95% CI 0.039 to 0.368Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9243 · Mean difference (final values): 0.008 · 95% CI -0.164 to 0.181Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0201 · Mean difference (final values): 0.210 · 95% CI 0.033 to 0.386Mean difference (final values) = Least squares mean difference
SecondaryPain Interference Index Score as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Pain interference index = average of pain interference question (Q) 5A to 5G. Questions were asked as follows: how, during the past 24 hours, has pain interfered with general activity (Q5A), mood (Q5B), walking ability (Q5C), normal work (outside home and housework) (Q5D), relations with other people (Q5E), sleep (Q5F), enjoyment of life (Q5G). Scale: 0=does not interfere to 10=completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference Index Score as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)3.427 ± 0.2303.488 ± 0.2303.887 ± 0.246
Week 2 (n=86, 78, 80)2.969 ± 0.2362.814 ± 0.2453.037 ± 0.251
Week 4 (n=77, 69, 67)2.162 ± 0.2021.996 ± 0.2082.094 ± 0.224
Week 6/ET (n=78, 67, 71)1.597 ± 0.1991.637 ± 0.2141.662 ± 0.215
Month 3 (n=30, 32, 35)1.139 ± 0.3671.335 ± 0.3751.629 ± 0.366
Month 6 (n=31, 25, 27)1.513 ± 0.2641.300 ± 0.2410.852 ± 0.253
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1537 · Mean difference (final values): -0.460 · 95% CI -1.093 to 0.173Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2208 · Mean difference (final values): -0.398 · 95% CI -1.038 to 0.241Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8355 · Mean difference (final values): -0.068 · 95% CI -0.707 to 0.572Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5024 · Mean difference (final values): -0.222 · 95% CI -0.875 to 0.430Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8116 · Mean difference (final values): 0.067 · 95% CI -0.489 to 0.624Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7325 · Mean difference (final values): -0.099 · 95% CI -0.667 to 0.469Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8133 · Mean difference (final values): -0.066 · 95% CI -0.614 to 0.482Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9307 · Mean difference (final values): -0.025 · 95% CI -0.588 to 0.538Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2682 · Mean difference (final values): -0.490 · 95% CI -1.364 to 0.385Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4784 · Mean difference (final values): -0.294 · 95% CI -1.116 to 0.528Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0255 · Mean difference (final values): 0.661 · 95% CI 0.084 to 1.239Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1591 · Mean difference (final values): 0.448 · 95% CI -0.180 to 1.076Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With Relations With People as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With Relations With People as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)1.837 ± 0.2661.716 ± 0.2662.624 ± 0.284
Week 2 (n=86, 78, 80)1.566 ± 0.2311.370 ± 0.2401.671 ± 0.246
Week 4 (n=77, 69, 67)1.004 ± 0.2151.162 ± 0.2221.187 ± 0.238
Week 6/ET (n=78, 67, 71)0.544 ± 0.1710.845 ± 0.1840.898 ± 0.185
Month 3 (n=30, 32, 35)0.253 ± 0.3770.861 ± 0.3771.364 ± 0.365
Month 6 (n=31, 25, 27)0.802 ± 0.2451.060 ± 0.2260.626 ± 0.235
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0359 · Mean difference (final values): -0.786 · 95% CI -1.520 to -0.052Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0161 · Mean difference (final values): -0.907 · 95% CI -1.644 to -0.170Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7416 · Mean difference (final values): -0.105 · 95% CI -0.733 to 0.523Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3527 · Mean difference (final values): -0.301 · 95% CI -0.939 to 0.336Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5419 · Mean difference (final values): -0.184 · 95% CI -0.776 to 0.409Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9333 · Mean difference (final values): -0.026 · 95% CI -0.628 to 0.577Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1420 · Mean difference (final values): -0.354 · 95% CI -0.827 to 0.120Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8290 · Mean difference (final values): -0.053 · 95% CI -0.535 to 0.429Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0138 · Mean difference (final values): -1.111 · 95% CI -1.989 to -0.233Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2300 · Mean difference (final values): -0.503 · 95% CI -1.332 to 0.325Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5151 · Mean difference (final values): 0.175 · 95% CI -0.360 to 0.711Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1460 · Mean difference (final values): 0.433 · 95% CI -0.155 to 1.022Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With Enjoyment of Life as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With Enjoyment of Life as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)3.487 ± 0.3303.769 ± 0.3303.744 ± 0.354
Week 2 (n=86, 78, 80)2.945 ± 0.3132.802 ± 0.3252.953 ± 0.334
Week 4 (n=77, 69, 67)2.152 ± 0.2602.042 ± 0.2681.768 ± 0.289
Week 6/ET (n=78, 67, 71)1.535 ± 0.2471.720 ± 0.2661.696 ± 0.267
Month 3 (n=30, 32, 35)0.944 ± 0.4971.467 ± 0.5131.368 ± 0.509
Month 6 (n=31, 25, 27)1.657 ± 0.4041.658 ± 0.3670.663 ± 0.389
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5786 · Mean difference (final values): -0.258 · 95% CI -1.170 to 0.655Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9570 · Mean difference (final values): 0.025 · 95% CI -0.895 to 0.946Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9860 · Mean difference (final values): -0.008 · 95% CI -0.862 to 0.847Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7336 · Mean difference (final values): -0.151 · 95% CI -1.021 to 0.720Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2939 · Mean difference (final values): 0.384 · 95% CI -0.336 to 1.104Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4615 · Mean difference (final values): 0.274 · 95% CI -0.459 to 1.008Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6433 · Mean difference (final values): -0.161 · 95% CI -0.845 to 0.523Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9466 · Mean difference (final values): 0.024 · 95% CI -0.678 to 0.726Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4967 · Mean difference (final values): -0.424 · 95% CI -1.660 to 0.812Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8659 · Mean difference (final values): 0.099 · 95% CI -1.060 to 1.257Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0311 · Mean difference (final values): 0.994 · 95% CI 0.093 to 1.895Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0441 · Mean difference (final values): 0.995 · 95% CI 0.027 to 1.962Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With General Activity as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With General Activity as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)3.794 ± 0.3174.499 ± 0.3154.764 ± 0.336
Week 2 (n=86, 78, 80)3.254 ± 0.2783.526 ± 0.2883.524 ± 0.294
Week 4 (n=77, 69, 67)2.470 ± 0.2372.417 ± 0.2442.427 ± 0.260
Week 6/ET (n=78, 67, 71)2.109 ± 0.2451.902 ± 0.2632.028 ± 0.263
Month 3 (n=30, 32, 35)1.861 ± 0.5051.547 ± 0.5071.969 ± 0.492
Month 6 (n=31, 25, 27)1.738 ± 0.4121.717 ± 0.3761.410 ± 0.394
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0284 · Mean difference (final values): -0.969 · 95% CI -1.835 to -0.104Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5516 · Mean difference (final values): -0.265 · 95% CI -1.141 to 0.611Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4790 · Mean difference (final values): -0.270 · 95% CI -1.020 to 0.480Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9947 · Mean difference (final values): 0.003 · 95% CI -0.765 to 0.770Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8943 · Mean difference (final values): 0.044 · 95% CI -0.605 to 0.692Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9767 · Mean difference (final values): -0.010 · 95% CI -0.674 to 0.654Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8117 · Mean difference (final values): 0.081 · 95% CI -0.590 to 0.752Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7216 · Mean difference (final values): -0.125 · 95% CI -0.818 to 0.567Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8558 · Mean difference (final values): -0.108 · 95% CI -1.286 to 1.070Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4501 · Mean difference (final values): -0.422 · 95% CI -1.530 to 0.685Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4682 · Mean difference (final values): 0.328 · 95% CI -0.570 to 1.227Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5347 · Mean difference (final values): 0.307 · 95% CI -0.675 to 1.289Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With Mood as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With Mood as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)2.588 ± 0.2922.418 ± 0.2913.354 ± 0.310
Week 2 (n=86, 78, 80)2.640 ± 0.2922.115 ± 0.3032.554 ± 0.308
Week 4 (n=77, 69, 67)1.590 ± 0.2531.511 ± 0.2611.530 ± 0.279
Week 6/ET (n=78, 67, 71)1.053 ± 0.2301.171 ± 0.2471.325 ± 0.247
Month 3 (n=30, 32, 35)0.632 ± 0.3280.956 ± 0.3391.334 ± 0.322
Month 6 (n=31, 25, 27)1.201 ± 0.3260.832 ± 0.2970.369 ± 0.313
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0613 · Mean difference (final values): -0.765 · 95% CI -1.568 to 0.037Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0230 · Mean difference (final values): -0.936 · 95% CI -1.741 to -0.130Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8306 · Mean difference (final values): 0.086 · 95% CI -0.703 to 0.875Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2814 · Mean difference (final values): -0.439 · 95% CI -1.242 to 0.363Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8637 · Mean difference (final values): 0.061 · 95% CI -0.636 to 0.757Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9585 · Mean difference (final values): -0.019 · 95% CI -0.727 to 0.689Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3975 · Mean difference (final values): -0.272 · 95% CI -0.906 to 0.361Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6386 · Mean difference (final values): -0.154 · 95% CI -0.799 to 0.491Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0813 · Mean difference (final values): -0.702 · 95% CI -1.493 to 0.089Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3100 · Mean difference (final values): -0.378 · 95% CI -1.114 to 0.358Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0231 · Mean difference (final values): 0.831 · 95% CI 0.118 to 1.545Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2367 · Mean difference (final values): 0.463 · 95% CI -0.311 to 1.237Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With Walking Ability as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With Walking Ability as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)4.918 ± 0.3204.728 ± 0.3194.982 ± 0.342
Week 2 (n=86, 78, 80)3.297 ± 0.2783.344 ± 0.2893.425 ± 0.296
Week 4 (n=77, 69, 67)2.646 ± 0.2592.108 ± 0.2672.442 ± 0.286
Week 6/ET (n=78, 67, 71)2.004 ± 0.2371.886 ± 0.2541.742 ± 0.256
Month 3 (n=30, 32, 35)1.439 ± 0.4191.907 ± 0.4341.928 ± 0.414
Month 6 (n=31, 25, 27)1.573 ± 0.3221.391 ± 0.2931.126 ± 0.308
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8868 · Mean difference (final values): -0.064 · 95% CI -0.947 to 0.820Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5733 · Mean difference (final values): -0.254 · 95% CI -1.142 to 0.634Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7385 · Mean difference (final values): -0.128 · 95% CI -0.884 to 0.628Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8353 · Mean difference (final values): -0.081 · 95% CI -0.849 to 0.687Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5737 · Mean difference (final values): 0.204 · 95% CI -0.510 to 0.918Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3640 · Mean difference (final values): -0.335 · 95% CI -1.060 to 0.391Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4315 · Mean difference (final values): 0.262 · 95% CI -0.393 to 0.917Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6727 · Mean difference (final values): 0.143 · 95% CI -0.525 to 0.812Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3361 · Mean difference (final values): -0.489 · 95% CI -1.496 to 0.517Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9634 · Mean difference (final values): -0.022 · 95% CI -0.955 to 0.912Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2098 · Mean difference (final values): 0.446 · 95% CI -0.257 to 1.150Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4900 · Mean difference (final values): 0.265 · 95% CI -0.497 to 1.027Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With Normal Work as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With Normal Work as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=82, 77, 72)4.879 ± 0.3904.738 ± 0.3954.873 ± 0.418
Week 2 (n=86, 78, 79)4.010 ± 0.3353.539 ± 0.3473.831 ± 0.355
Week 4 (n=77, 69, 67)2.833 ± 0.2752.500 ± 0.2852.895 ± 0.305
Week 6/ET (n=78, 67, 71)2.133 ± 0.2692.152 ± 0.2912.040 ± 0.291
Month 3 (n=30, 32, 35)1.797 ± 0.5101.731 ± 0.5202.264 ± 0.507
Month 6 (n=31, 25, 27)1.627 ± 0.2881.349 ± 0.2631.029 ± 0.276
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9912 · Mean difference (final values): 0.006 · 95% CI -1.070 to 1.082Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8076 · Mean difference (final values): -0.135 · 95% CI -1.227 to 0.957Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6978 · Mean difference (final values): 0.179 · 95% CI -0.727 to 1.085Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5344 · Mean difference (final values): -0.293 · 95% CI -1.219 to 0.634Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8721 · Mean difference (final values): -0.062 · 95% CI -0.819 to 0.695Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3179 · Mean difference (final values): -0.395 · 95% CI -1.173 to 0.383Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8037 · Mean difference (final values): 0.094 · 95% CI -0.648 to 0.835Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7731 · Mean difference (final values): 0.113 · 95% CI -0.656 to 0.881Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4461 · Mean difference (final values): -0.468 · 95% CI -1.684 to 0.748Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3568 · Mean difference (final values): -0.533 · 95% CI -1.679 to 0.612Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0623 · Mean difference (final values): 0.598 · 95% CI -0.032 to 1.227Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3529 · Mean difference (final values): 0.320 · 95% CI -0.364 to 1.005Mean difference (final values) = Least squares mean difference
SecondaryPain Interference With Sleep as Measured by the m-BPI-sf

m-BPI-sf questionnaire (7-items) assessed pain interference with functional activities during the past 24 hours. Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET, Month 3, Month 6
Reported as:
Least squares mean · scores on a scale
Pain Interference With Sleep as Measured by the m-BPI-sf
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=83, 80, 74)2.696 ± 0.2992.642 ± 0.2993.307 ± 0.318
Week 2 (n=86, 78, 80)3.139 ± 0.3333.015 ± 0.3453.587 ± 0.353
Week 4 (n=77, 69, 67)2.478 ± 0.2782.166 ± 0.2882.668 ± 0.308
Week 6/ET (n=78, 67, 71)1.847 ± 0.2751.701 ± 0.2962.070 ± 0.296
Month 3 (n=30, 32, 35)1.276 ± 0.5370.941 ± 0.5481.499 ± 0.526
Month 6 (n=31, 25, 27)1.963 ± 0.4821.005 ± 0.4390.778 ± 0.464
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1448 · Mean difference (final values): -0.611 · 95% CI -1.434 to 0.212Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1148 · Mean difference (final values): -0.665 · 95% CI -1.494 to 0.163Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3285 · Mean difference (final values): -0.448 · 95% CI -1.350 to 0.454Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2205 · Mean difference (final values): -0.572 · 95% CI -1.490 to 0.346Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6266 · Mean difference (final values): -0.190 · 95% CI -0.958 to 0.578Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2077 · Mean difference (final values): -0.502 · 95% CI -1.284 to 0.281Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5626 · Mean difference (final values): -0.223 · 95% CI -0.982 to 0.536Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3507 · Mean difference (final values): -0.368 · 95% CI -1.145 to 0.408Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7276 · Mean difference (final values): -0.224 · 95% CI -1.498 to 1.050Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3530 · Mean difference (final values): -0.558 · 95% CI -1.748 to 0.631Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0283 · Mean difference (final values): 1.186 · 95% CI 0.130 to 2.242Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6934 · Mean difference (final values): 0.227 · 95% CI -0.918 to 1.372Mean difference (final values) = Least squares mean difference
SecondaryDaily and Weekly Worst Pain During the Hospital Stay and Post Discharge Assessed by the Pain Numerical Rating Scale (NRS)

Subject rated scale for worst pain over the last 24 hours. Scores ranged from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.

Time frame:
12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, and 192 hours during the hospital stay, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
Daily and Weekly Worst Pain During the Hospital Stay and Post Discharge Assessed by the Pain Numerical Rating Scale (NRS)
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
12 hours (n=29, 28, 28)7.217 ± 0.5977.002 ± 0.6498.770 ± 0.635
24 hours (n=82, 79, 74)7.477 ± 0.2987.290 ± 0.3017.201 ± 0.311
48 hours (n=78, 82, 75)7.041 ± 0.2676.740 ± 0.2647.079 ± 0.279
72 hours (n=56, 52, 55)6.322 ± 0.3335.977 ± 0.3505.964 ± 0.343
96 hours (n=20, 21, 26)6.703 ± 0.6244.711 ± 0.6186.556 ± 0.598
120 hours (n=5, 3, 9)5.915 ± 0.8194.346 ± 1.4467.056 ± 0.663
Week 2 (n=79, 72, 72)5.255 ± 0.2095.592 ± 0.2235.396 ± 0.229
Week 4 (n=76, 65, 67)4.134 ± 0.2204.043 ± 0.2414.280 ± 0.247
Week 6/ET (n=61, 55, 59)3.455 ± 0.2673.425 ± 0.2763.350 ± 0.292
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0476 · Mean difference (final values): -1.553 · 95% CI -3.089 to -0.017Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0237 · Mean difference (final values): -1.768 · 95% CI -3.293 to -0.243Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4925 · Mean difference (final values): 0.276 · 95% CI -0.516 to 1.069Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8299 · Mean difference (final values): 0.089 · 95% CI -0.727 to 0.905Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9185 · Mean difference (final values): -0.038 · 95% CI -0.766 to 0.691Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3619 · Mean difference (final values): -0.339 · 95% CI -1.070 to 0.392Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4309 · Mean difference (final values): 0.358 · 95% CI -0.538 to 1.254Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9778 · Mean difference (final values): 0.013 · 95% CI -0.895 to 0.921Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8503 · Mean difference (final values): 0.147 · 95% CI -1.411 to 1.706Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0183 · Mean difference (final values): -1.845 · 95% CI -3.364 to -0.326Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2860 · Mean difference (final values): -1.141 · 95% CI -3.598 to 1.316Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2040 · Mean difference (final values): -2.710 · 95% CI -7.479 to 2.060Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6332 · Mean difference (final values): -0.141 · 95% CI -0.722 to 0.440Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5183 · Mean difference (final values): 0.196 · 95% CI -0.402 to 0.794Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6341 · Mean difference (final values): -0.146 · 95% CI -0.750 to 0.458Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4607 · Mean difference (final values): -0.236 · 95% CI -0.868 to 0.395Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7499 · Mean difference (final values): 0.104 · 95% CI -0.541 to 0.750Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8231 · Mean difference (final values): 0.075 · 95% CI -0.584 to 0.733Mean difference (final values) = Least squares mean difference
SecondaryDaily and Weekly Average Pain During the Hospital Stay and Post Discharge Assessed by the Pain NRS

Subject rated scale for average pain intensity over the last 24 hours. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine). Weekly mean scores were calculated post-discharge.

Time frame:
12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, and 192 hours during the hospital stay, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
Daily and Weekly Average Pain During the Hospital Stay and Post Discharge Assessed by the Pain NRS
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
12 hours (n=29, 28, 28)5.712 ± 0.5504.845 ± 0.5936.748 ± 0.600
24 hours (n=81, 79, 74)4.961 ± 0.2554.614 ± 0.2574.918 ± 0.266
48 hours (n=78, 82, 75)4.518 ± 0.2384.309 ± 0.2364.515 ± 0.249
72 hours (n=56, 51, 55)4.281 ± 0.2803.740 ± 0.2984.186 ± 0.290
96 hours (n=20, 21, 26)4.842 ± 0.5143.126 ± 0.5034.741 ± 0.488
120 hours (n=5, 3, 9)4.211 ± 1.0022.940 ± 1.5664.287 ± 0.759
Week 2 (n=79, 72, 71)3.691 ± 0.1863.974 ± 0.1983.987 ± 0.206
Week 4 (n=76, 65, 67)2.956 ± 0.1802.845 ± 0.1973.163 ± 0.203
Week 6/ET (n=60, 54, 59)2.374 ± 0.2152.385 ± 0.2252.389 ± 0.234
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1486 · Mean difference (final values): -1.036 · 95% CI -2.452 to 0.379Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0089 · Mean difference (final values): -1.903 · 95% CI -3.311 to -0.494Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8995 · Mean difference (final values): 0.044 · 95% CI -0.635 to 0.722Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3918 · Mean difference (final values): -0.303 · 95% CI -1.000 to 0.394Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9942 · Mean difference (final values): 0.002 · 95% CI -0.648 to 0.652Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5352 · Mean difference (final values): -0.206 · 95% CI -0.859 to 0.448Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8055 · Mean difference (final values): 0.094 · 95% CI -0.662 to 0.850Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2560 · Mean difference (final values): -0.446 · 95% CI -1.220 to 0.327Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8744 · Mean difference (final values): 0.102 · 95% CI -1.184 to 1.387Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0115 · Mean difference (final values): -1.614 · 95% CI -2.851 to -0.378Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9497 · Mean difference (final values): -0.077 · 95% CI -3.047 to 2.893Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5288 · Mean difference (final values): -1.347 · 95% CI -6.467 to 3.773Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2595 · Mean difference (final values): -0.296 · 95% CI -0.813 to 0.220Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9605 · Mean difference (final values): -0.013 · 95% CI -0.546 to 0.519Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4107 · Mean difference (final values): -0.207 · 95% CI -0.702 to 0.288Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2271 · Mean difference (final values): -0.318 · 95% CI -0.836 to 0.200Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9552 · Mean difference (final values): -0.015 · 95% CI -0.535 to 0.506Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9899 · Mean difference (final values): -0.003 · 95% CI -0.533 to 0.526Mean difference (final values) = Least squares mean difference
SecondaryCurrent Pain During the Hospital Stay Assessed by the Pain NRS

Subject rated scale for average pain intensity over the last 24 hours. Pain was assessed using the question "How much pain do you have right now?" Scores range from 0 (no pain) to 10 (most possible pain).

Time frame:
4, 8, 12, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, 184, and 192 hours during the hospital stay
Reported as:
Least squares mean · scores on a scale
Current Pain During the Hospital Stay Assessed by the Pain NRS
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
4 hours (n=84, 84, 78)4.940 ± 0.3453.554 ± 0.3444.363 ± 0.361
8 hours (n=82, 79, 75)5.083 ± 0.3054.529 ± 0.3125.119 ± 0.323
12 hours (n=66, 68, 64)4.779 ± 0.3854.068 ± 0.3754.784 ± 0.376
24 hours (n=87, 88, 82)4.500 ± 0.2654.545 ± 0.2624.836 ± 0.277
32 hours (n=79, 78, 69)4.450 ± 0.2934.507 ± 0.2964.345 ± 0.315
40 hours (n=62, 55, 55)3.720 ± 0.4013.821 ± 0.4123.902 ± 0.408
48 hours (n=78, 72, 70)4.095 ± 0.2764.069 ± 0.2843.785 ± 0.295
56 hours (n=62, 56, 57)4.015 ± 0.3293.358 ± 0.3453.760 ± 0.343
64 hours (n=46, 37, 45)4.220 ± 0.4583.492 ± 0.4804.578 ± 0.423
72 hours (n=51, 45, 45)3.971 ± 0.3443.271 ± 0.3793.826 ± 0.385
80 hours (n=19, 24, 24)5.312 ± 0.6782.403 ± 0.6244.285 ± 0.691
88 hours (n=16, 13, 20)4.265 ± 0.7142.767 ± 0.8033.914 ± 0.730
96 hours (n=16, 14, 20)3.525 ± 0.7292.532 ± 0.7732.658 ± 0.737
104 hours (n=7, 3, 7)3.501 ± 0.9082.680 ± 1.3821.829 ± 0.972
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2211 · Mean difference (final values): 0.578 · 95% CI -0.350 to 1.506Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0916 · Mean difference (final values): -0.809 · 95% CI -1.750 to 0.132Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9312 · Mean difference (final values): -0.036 · 95% CI -0.863 to 0.791Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1658 · Mean difference (final values): -0.591 · 95% CI -1.428 to 0.247Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9921 · Mean difference (final values): -0.005 · 95% CI -0.958 to 0.948Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1367 · Mean difference (final values): -0.715 · 95% CI -1.660 to 0.229Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3561 · Mean difference (final values): -0.336 · 95% CI -1.053 to 0.380Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4260 · Mean difference (final values): -0.291 · 95% CI -1.012 to 0.429Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7975 · Mean difference (final values): 0.105 · 95% CI -0.703 to 0.914Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6947 · Mean difference (final values): 0.162 · 95% CI -0.650 to 0.974Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6954 · Mean difference (final values): -0.182 · 95% CI -1.101 to 0.736Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8665 · Mean difference (final values): -0.081 · 95% CI -1.032 to 0.870Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4216 · Mean difference (final values): 0.311 · 95% CI -0.450 to 1.072Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4673 · Mean difference (final values): 0.285 · 95% CI -0.487 to 1.056Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5624 · Mean difference (final values): 0.255 · 95% CI -0.614 to 1.125Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3705 · Mean difference (final values): -0.402 · 95% CI -1.286 to 0.482Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4539 · Mean difference (final values): -0.358 · 95% CI -1.302 to 0.586Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0373 · Mean difference (final values): -1.086 · 95% CI -2.107 to -0.065Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7600 · Mean difference (final values): 0.146 · 95% CI -0.796 to 1.087Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2506 · Mean difference (final values): -0.555 · 95% CI -1.507 to 0.397Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2567 · Mean difference (final values): 1.027 · 95% CI -0.770 to 2.823Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0167 · Mean difference (final values): -1.882 · 95% CI -3.408 to -0.356Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6953 · Mean difference (final values): 0.352 · 95% CI -1.456 to 2.159Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2080 · Mean difference (final values): -1.147 · 95% CI -2.962 to 0.668Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3805 · Mean difference (final values): 0.867 · 95% CI -1.116 to 2.849Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8900 · Mean difference (final values): -0.126 · 95% CI -1.965 to 1.713Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1821 · Mean difference (final values): 1.672 · 95% CI -1.103 to 4.448Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6505 · Mean difference (final values): 0.851 · 95% CI -3.693 to 5.395Mean difference (final values) = Least squares mean difference
SecondaryPain-Related Sleep Interference Post Surgery

The NRS-Sleep: subject rated 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]) rating how pain has interfered with sleep during the past 24 hours. Weekly mean scores were calculated post hospital discharge.

Time frame:
24 hours, 48 hours, 72 hours, 96 hours 120 hours, 144 hours, 168 hours, and 192 hours post-surgery, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
Pain-Related Sleep Interference Post Surgery
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=86, 86, 81)4.452 ± 0.3593.671 ± 0.3645.481 ± 0.376
48 hours (n=82, 82, 77)3.830 ± 0.2933.408 ± 0.2964.027 ± 0.309
72 hours (n=59, 58, 59)2.926 ± 0.3322.609 ± 0.3493.645 ± 0.345
96 hours (n=20, 21, 24)4.087 ± 0.5391.645 ± 0.5223.213 ± 0.563
120 hours (n=6, 4, 7)3.194 ± 1.6657.237 ± 2.5631.328 ± 1.598
Week 2 (n=80, 73, 71)3.837 ± 0.2174.128 ± 0.2294.256 ± 0.239
Week 4 (n=76, 65, 67)3.181 ± 0.2163.042 ± 0.2363.532 ± 0.241
Week 6/ET (n=61, 56, 57)2.484 ± 0.2612.592 ± 0.2652.748 ± 0.284
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0388 · Mean difference (final values): -1.029 · 95% CI -2.004 to -0.053Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0004 · Mean difference (final values): -1.810 · 95% CI -2.798 to -0.822Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6274 · Mean difference (final values): -0.197 · 95% CI -0.995 to 0.601Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1350 · Mean difference (final values): -0.619 · 95% CI -1.432 to 0.194Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1106 · Mean difference (final values): -0.719 · 95% CI -1.605 to 0.166Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0248 · Mean difference (final values): -1.036 · 95% CI -1.939 to -0.133Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2335 · Mean difference (final values): 0.874 · 95% CI -0.582 to 2.330Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0258 · Mean difference (final values): -1.568 · 95% CI -2.939 to -0.198Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3878 · Mean difference (final values): 1.866 · 95% CI -3.207 to 6.939Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1762 · Mean difference (final values): 5.909 · 95% CI -3.740 to 15.559Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1754 · Mean difference (final values): -0.515 · 95% CI -1.261 to 0.231Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1413 · Mean difference (final values): -0.569 · 95% CI -1.329 to 0.191Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1731 · Mean difference (final values): -0.419 · 95% CI -1.023 to 0.185Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6829 · Mean difference (final values): -0.128 · 95% CI -0.747 to 0.490Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2436 · Mean difference (final values): -0.351 · 95% CI -0.943 to 0.241Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1190 · Mean difference (final values): -0.490 · 95% CI -1.108 to 0.127Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4117 · Mean difference (final values): -0.264 · 95% CI -0.897 to 0.369Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6294 · Mean difference (final values): -0.156 · 95% CI -0.794 to 0.482Mean difference (final values) = Least squares mean difference
SecondaryChange From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery

VAS-Anxiety was administered to measure pre-operative anxiety. Score: 0 = no anxiety to 100 = worst imaginable anxiety.

Time frame:
Day 1, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours prior to surgery
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Visual Analogue Scale for Anxiety (VAS-Anxiety) Score Prior to Surgery
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Day 1 (n=83, 79, 78)6.133 ± 2.3957.103 ± 2.4506.992 ± 2.523
1 hour (n=68, 67, 59)6.974 ± 2.7873.272 ± 2.8056.085 ± 3.013
2 hours (n=75, 76, 63)3.792 ± 2.8606.818 ± 2.8446.454 ± 3.126
3 hours (n=52, 58, 63)7.477 ± 3.4667.588 ± 3.1887.313 ± 3.108
4 hours (n=19, 17, 20)8.218 ± 5.8030.109 ± 6.15010.133 ± 5.527
5 hours (n=3, 4, 8)71.190 ± 16.88629.819 ± 7.644-15.145 ± 6.572
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7958 · Mean difference (final values): -0.859 · 95% CI -7.391 to 5.673Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9733 · Mean difference (final values): 0.111 · 95% CI -6.436 to 6.659Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8220 · Mean difference (final values): 0.889 · 95% CI -6.898 to 8.675Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4736 · Mean difference (final values): -2.813 · 95% CI -10.542 to 4.917Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5113 · Mean difference (final values): -2.662 · 95% CI -10.639 to 5.316Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9266 · Mean difference (final values): 0.365 · 95% CI -7.425 to 8.154Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9699 · Mean difference (final values): 0.164 · 95% CI -8.423 to 8.751Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9482 · Mean difference (final values): 0.275 · 95% CI -8.085 to 8.635Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7969 · Mean difference (final values): -1.915 · 95% CI -16.842 to 13.012Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1991 · Mean difference (final values): -10.023 · 95% CI -25.533 to 5.487Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0321 · Mean difference (final values): 86.335 · 95% CI 13.976 to 158.693Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0353 · Mean difference (final values): 44.964 · 95% CI 5.837 to 84.091Mean difference (final values) = Least squares mean difference
SecondaryTimed Up-and-Go (TUG)

TUG: time taken in seconds to rise from a standard arm chair, walk to a line on the floor 3 meters away, turn, return and sit down again.

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, 120 hours, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · seconds
Timed Up-and-Go (TUG)
secondsPregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=45, 47, 46)76.153 ± 10.44979.973 ± 8.71982.964 ± 10.174
48 hours (n=69, 70, 64)80.027 ± 8.60179.548 ± 8.11186.842 ± 8.927
72 hours (n=46, 46, 46)66.228 ± 8.42968.373 ± 8.56180.142 ± 9.276
96 hours (n=14, 14, 22)110.780 ± 45.43743.021 ± 36.75170.271 ± 37.742
120 hours (n=5, 2, 5)52.591 ± 5.102NA ± NA34.078 ± 4.700
Week 2 (n=78, 71, 72)22.322 ± 2.08721.332 ± 2.09121.678 ± 2.113
Week 4 (n=73, 65, 63)18.072 ± 1.53718.145 ± 1.52716.535 ± 1.563
Week 6/ET (n=75, 60, 63)12.694 ± 1.22615.140 ± 1.43713.813 ± 1.408
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5736 · Mean difference (final values): -6.812 · 95% CI -30.792 to 17.169Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8003 · Mean difference (final values): -2.991 · 95% CI -26.438 to 20.455Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5125 · Mean difference (final values): -6.815 · 95% CI -27.369 to 13.740Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4773 · Mean difference (final values): -7.294 · 95% CI -27.563 to 12.976Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2142 · Mean difference (final values): -13.915 · 95% CI -36.055 to 8.226Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2989 · Mean difference (final values): -11.769 · 95% CI -34.197 to 10.659Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3829 · Mean difference (final values): 40.510 · 95% CI -53.429 to 134.449Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5531 · Mean difference (final values): -27.250 · 95% CI -120.59 to 66.092Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2738 · Mean difference (final values): 18.513 · 95% CI -89.376 to 126.402Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7987 · Mean difference (final values): 0.644 · 95% CI -4.343 to 5.630Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8875 · Mean difference (final values): -0.346 · 95% CI -5.177 to 4.485Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4319 · Mean difference (final values): 1.537 · 95% CI -2.324 to 5.398Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4070 · Mean difference (final values): 1.610 · 95% CI -2.223 to 5.443Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4968 · Mean difference (final values): -1.119 · 95% CI -4.371 to 2.133Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4270 · Mean difference (final values): 1.327 · 95% CI -1.972 to 4.626Mean difference (final values) = Least squares mean difference
SecondaryRange of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee

The degree of active (patient moving the knee) knee flexion and extension tolerated by each subject was recorded. Active ROM in the sitting position was assessed with a goniometer.

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, and 120 hours post surgery, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · degrees
Range of Motion (ROM) Assessment of the Active Flexion of the Surgical Knee
degreesPregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=74, 71, 68)54.877 ± 2.19460.744 ± 2.24855.738 ± 2.287
48 hours (n=76, 78, 67)69.981 ± 1.98473.370 ± 1.96769.178 ± 2.184
72 hours (n=52, 52, 50)76.516 ± 2.27479.535 ± 2.34875.588 ± 2.406
96 hours (n=17, 17, 24)78.624 ± 3.28779.500 ± 2.93674.194 ± 2.969
120 hours (n=6, 3, 6)80.694 ± 4.89072.694 ± 7.88181.765 ± 5.625
Week 2 (n=73, 67, 69)89.917 ± 1.58990.332 ± 1.65687.992 ± 1.711
Week 4 (n=65, 63, 62)98.883 ± 1.870102.237 ± 1.91496.921 ± 2.017
Week 6/ET (n=67, 54, 63)105.352 ± 1.845106.252 ± 2.137103.980 ± 2.051
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7742 · Mean difference (final values): -0.862 · 95% CI -6.775 to 5.052Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0996 · Mean difference (final values): 5.006 · 95% CI -0.960 to 10.971Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7738 · Mean difference (final values): 0.803 · 95% CI -4.698 to 6.304Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1328 · Mean difference (final values): 4.192 · 95% CI -1.284 to 9.669Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7585 · Mean difference (final values): 0.928 · 95% CI -5.027 to 6.882Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1900 · Mean difference (final values): 3.946 · 95% CI -1.979 to 9.871Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2365 · Mean difference (final values): 4.430 · 95% CI -3.004 to 11.865Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1616 · Mean difference (final values): 5.306 · 95% CI -2.202 to 12.814Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8819 · Mean difference (final values): -1.071 · 95% CI -17.98 to 15.838Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4676 · Mean difference (final values): -9.071 · 95% CI -37.70 to 19.558Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3813 · Mean difference (final values): 1.925 · 95% CI -2.403 to 6.254Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2966 · Mean difference (final values): 2.341 · 95% CI -2.070 to 6.751Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4474 · Mean difference (final values): 1.962 · 95% CI -3.122 to 7.046Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0416 · Mean difference (final values): 5.316 · 95% CI 0.204 to 10.427Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5935 · Mean difference (final values): 1.372 · 95% CI -3.694 to 6.438Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3966 · Mean difference (final values): 2.272 · 95% CI -3.006 to 7.551Mean difference (final values) = Least squares mean difference
SecondaryROM Assessment of the Passive Flexion of the Surgical Knee

The degree of passive (movement of the knee with the aid of physical therapist or designee) knee flexion and extension tolerated by each subject was recorded. Passive ROM in the sitting position was assessed with a goniometer.

Time frame:
24 hours, 48 hours, 72 hours, 96 hours, and 120 hours post surgery, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · degrees
ROM Assessment of the Passive Flexion of the Surgical Knee
degreesPregabalin (150 mg)Pregabalin (300 mg)Placebo
24 hours (n=81, 76, 73)66.720 ± 1.99071.523 ± 2.09864.991 ± 2.093
48 hours (n=78, 80, 70)77.714 ± 1.69581.322 ± 1.67576.813 ± 1.809
72 hours (n=53, 50, 53)84.154 ± 1.95288.119 ± 2.04180.984 ± 1.971
96 hours (n=17, 17, 24)86.471 ± 3.55391.460 ± 3.17480.287 ± 3.210
120 hours (n=5, 3, 6)92.160 ± 1.51797.160 ± 2.38179.218 ± 1.682
Week 2 (n=79, 71, 73)94.767 ± 1.52096.973 ± 1.60693.642 ± 1.647
Week 4 (n=72, 62, 65)104.548 ± 1.680107.703 ± 1.835101.932 ± 1.851
Week 6/ET (n=74, 60, 66)110.318 ± 1.629111.348 ± 1.884108.944 ± 1.848
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5117 · Mean difference (final values): 1.729 · 95% CI -3.457 to 6.916Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0154 · Mean difference (final values): 6.532 · 95% CI 1.258 to 11.805Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7022 · Mean difference (final values): 0.901 · 95% CI -3.738 to 5.540Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0557 · Mean difference (final values): 4.509 · 95% CI -0.110 to 9.129Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2161 · Mean difference (final values): 3.171 · 95% CI -1.874 to 8.215Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0058 · Mean difference (final values): 7.135 · 95% CI 2.098 to 12.172Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1283 · Mean difference (final values): 6.185 · 95% CI -1.853 to 14.223Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0080 · Mean difference (final values): 11.173 · 95% CI 3.056 to 19.291Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0018 · Mean difference (final values): 12.941 · 95% CI 7.414 to 18.468Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0038 · Mean difference (final values): 17.941 · 95% CI 8.859 to 27.023Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5953 · Mean difference (final values): 1.125 · 95% CI -3.045 to 5.296Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1267 · Mean difference (final values): 3.331 · 95% CI -0.952 to 7.613Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2647 · Mean difference (final values): 2.617 · 95% CI -1.997 to 7.231Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0181 · Mean difference (final values): 5.771 · 95% CI 0.995 to 10.548Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5507 · Mean difference (final values): 1.374 · 95% CI -3.161 to 5.910Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3164 · Mean difference (final values): 2.404 · 95% CI -2.317 to 7.124Mean difference (final values) = Least squares mean difference
SecondaryTime From End of Surgery to Meet Hospital Discharge Criteria

The analysis was performed by Kaplan-Meier method with log-rank test.

Time frame:
time from end of surgery up to 192 hours post surgery
Reported as:
Mean · hours
Time From End of Surgery to Meet Hospital Discharge Criteria
hoursPregabalin (150 mg)Pregabalin (300 mg)Placebo
Time From End of Surgery to Meet Hospital Discharge Criteria106.802 ± 6.059112.966 ± 7.70795.531 ± 3.385
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · Log Rank · p = 0.4365
  • Pregabalin (300 mg) vs Placebo · Log Rank · p = 0.4023
SecondaryTime From End of Surgery to Actual Discharge

The analysis was performed by Kaplan-Meier method with log-rank test.

Time frame:
time from end of surgery up to 192 hours post surgery
Reported as:
Mean · hours
Time From End of Surgery to Actual Discharge
hoursPregabalin (150 mg)Pregabalin (300 mg)Placebo
Time From End of Surgery to Actual Discharge75.709 ± 2.79873.906 ± 2.40478.451 ± 2.715
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · Log Rank · p = 0.4024
  • Pregabalin (300 mg) vs Placebo · Log Rank · p = 0.1910
SecondarySatisfaction With Current Pain Medication Measured by the Pain Treatment Satisfaction Scale (PTSS)

Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
Satisfaction With Current Pain Medication Measured by the Pain Treatment Satisfaction Scale (PTSS)
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=84, 84, 80)79.897 ± 1.80280.706 ± 1.80977.550 ± 1.890
Week 2 (n=22, 20, 18)85.274 ± 4.68985.294 ± 4.78280.148 ± 5.201
Week 4 (n=30, 27, 19)83.608 ± 3.01284.728 ± 3.01081.572 ± 3.765
Week 6/ET (n=32, 31, 40)74.618 ± 3.92276.925 ± 4.18771.962 ± 4.044
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3483 · Mean difference (final values): 2.347 · 95% CI -2.573 to 7.268Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2078 · Mean difference (final values): 3.155 · 95% CI -1.766 to 8.077Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.4299 · Mean difference (final values): 5.126 · 95% CI -7.836 to 18.088Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4482 · Mean difference (final values): 5.146 · 95% CI -8.400 to 18.693Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6472 · Mean difference (final values): 2.036 · 95% CI -6.818 to 10.890Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4992 · Mean difference (final values): 3.156 · 95% CI -6.129 to 12.442Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.6072 · Mean difference (final values): 2.656 · 95% CI -7.578 to 12.891Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.3146 · Mean difference (final values): 4.963 · 95% CI -4.789 to 14.714Mean difference (final values) = Least squares mean difference
SecondarySatisfaction With Medication Characteristics Measured by the PTSS

Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
Satisfaction With Medication Characteristics Measured by the PTSS
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=84, 84, 80)85.733 ± 1.67985.732 ± 1.68581.556 ± 1.761
Week 2 (n=22, 20, 18)91.880 ± 4.67687.869 ± 4.76984.583 ± 5.187
Week 4 (n=30, 27, 19)88.492 ± 2.69390.571 ± 2.69184.323 ± 3.366
Week 6/ET (n=32, 31, 40)82.339 ± 3.72984.571 ± 3.98076.908 ± 3.845
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.0739 · Mean difference (final values): 4.177 · 95% CI -0.407 to 8.760Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.0740 · Mean difference (final values): 4.176 · 95% CI -0.409 to 8.761Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2615 · Mean difference (final values): 7.298 · 95% CI -5.628 to 20.224Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.6266 · Mean difference (final values): 3.286 · 95% CI -10.22 to 16.795Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2963 · Mean difference (final values): 4.170 · 95% CI -3.747 to 12.086Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1375 · Mean difference (final values): 6.248 · 95% CI -2.054 to 14.550Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2703 · Mean difference (final values): 5.431 · 95% CI -4.298 to 15.161Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.1040 · Mean difference (final values): 7.663 · 95% CI -1.607 to 16.933Mean difference (final values) = Least squares mean difference
SecondarySatisfaction With Medication Efficacy Measured by the PTSS

Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

Time frame:
Discharge, Week 2, Week 4, Week 6/ET
Reported as:
Least squares mean · scores on a scale
Satisfaction With Medication Efficacy Measured by the PTSS
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=84, 84, 80)74.156 ± 2.27675.705 ± 2.28473.577 ± 2.387
Week 2 (n=22, 20, 18)78.669 ± 6.01082.724 ± 6.12975.713 ± 6.666
Week 4 (n=30, 27, 19)78.723 ± 3.81178.886 ± 3.80878.823 ± 4.763
Week 6/ET (n=32, 31, 40)66.887 ± 4.95869.367 ± 5.29267.015 ± 5.112
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.8545 · Mean difference (final values): 0.579 · 95% CI -5.635 to 6.793Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5006 · Mean difference (final values): 2.128 · 95% CI -4.088 to 8.344Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.7217 · Mean difference (final values): 2.956 · 95% CI -13.66 to 19.569Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.4203 · Mean difference (final values): 7.011 · 95% CI -10.35 to 24.372Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9859 · Mean difference (final values): -0.100 · 95% CI -11.30 to 11.102Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9915 · Mean difference (final values): 0.063 · 95% CI -11.68 to 11.811Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9843 · Mean difference (final values): -0.128 · 95% CI -13.06 to 12.808Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7055 · Mean difference (final values): 2.351 · 95% CI -9.974 to 14.677Mean difference (final values) = Least squares mean difference
SecondaryOverall Satisfaction Measured by the PTSS

Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

Time frame:
Discharge, Week 2, Week 4, and Week 6/ET
Reported as:
Least squares mean · scores on a scale
Overall Satisfaction Measured by the PTSS
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=12, 17, 15)1.845 ± 0.2471.654 ± 0.2021.821 ± 0.219
Week 2 (n=6, 4, 4)2.333 ± 0.8271.667 ± 0.6751.833 ± 0.893
Week 4 (n=4, 3, 4)1.149 ± 0.6152.433 ± 0.6792.478 ± 0.629
Week 6/ET (n=2, 5, 6)1.526 ± 1.3464.174 ± 0.7843.878 ± 0.765
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.9405 · Mean difference (final values): 0.024 · 95% CI -0.614 to 0.661Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.5641 · Mean difference (final values): -0.167 · 95% CI -0.749 to 0.415Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5226 · Mean difference (final values): 0.500 · 95% CI -1.181 to 2.181Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8557 · Mean difference (final values): -0.167 · 95% CI -2.156 to 1.823Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.1925 · Mean difference (final values): -1.328 · 95% CI -3.596 to 0.940Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9654 · Mean difference (final values): -0.045 · 95% CI -2.568 to 2.479Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.2350 · Mean difference (final values): -2.352 · 95% CI -6.712 to 2.008Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7420 · Mean difference (final values): 0.296 · 95% CI -1.806 to 2.399Mean difference (final values) = Least squares mean difference
SecondaryOverall Pain Relief Measured by the PTSS

Measure of subject satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment.

Time frame:
Discharge, Week 2, Week 4, and Week 6/ET
Reported as:
Least squares mean · scores on a scale
Overall Pain Relief Measured by the PTSS
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge (n=12, 17, 15)2.260 ± 0.2581.696 ± 0.2112.051 ± 0.229
Week 2 (n=6, 4, 4)2.333 ± 0.8271.667 ± 0.6751.833 ± 0.893
Week 4 (n=4, 3, 4)1.418 ± 0.7132.612 ± 0.7882.537 ± 0.730
Week 6/ET (n=2, 5, 6)2.067 ± 1.4034.233 ± 0.8173.900 ± 0.797
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5299 · Mean difference (final values): 0.208 · 95% CI -0.458 to 0.874Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.2442 · Mean difference (final values): -0.355 · 95% CI -0.964 to 0.253Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.5226 · Mean difference (final values): 0.500 · 95% CI -1.181 to 2.181Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.8557 · Mean difference (final values): -0.167 · 95% CI -2.156 to 1.823Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3240 · Mean difference (final values): -1.119 · 95% CI -3.751 to 1.512Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.9503 · Mean difference (final values): 0.075 · 95% CI -2.853 to 3.003Mean difference (final values) = Least squares mean difference
  • Pregabalin (150 mg) vs Placebo · ANOVA · p = 0.3618 · Mean difference (final values): -1.833 · 95% CI -6.379 to 2.712Mean difference (final values) = Least squares mean difference
  • Pregabalin (300 mg) vs Placebo · ANOVA · p = 0.7226 · Mean difference (final values): 0.333 · 95% CI -1.859 to 2.525Mean difference (final values) = Least squares mean difference
SecondaryNumber of Subjects With Global Evaluation of Study Medication Scores

The Global Evaluation of Study Medication is a subject-administered single item instrument that records the subject's overall impression (global evaluation) of the study medication by asking the following question: how would you rate the study medication you received for pain? The subject chooses based on a scale of 1 (poor), 2 (fair), 3 (good), or 4 (excellent).

Time frame:
Discharge, Week 2, Week 4, and Week 6/ET
Reported as:
Number · participants
Number of Subjects With Global Evaluation of Study Medication Scores
participantsPregabalin (150 mg)Pregabalin (300 mg)Placebo
Discharge, Excellent (n=85, 84, 78)312719
Discharge, Good (n=85, 84, 78)314639
Discharge, Fair (n=85, 84, 78)14612
Discharge, Poor (n=85, 84, 78)958
Week 2, Excellent (n=22, 20, 18)6105
Week 2, Good (n=22, 20, 18)1149
Week 2, Fair (n=22, 20, 18)341
Week 2, Poor (n=22, 20, 18)223
Week 4, Excellent (n=30, 27, 19)1397
Week 4, Good (n=30, 27, 19)11128
Week 4, Fair (n=30, 27, 19)433
Week 4, Poor (n=30, 27, 19)231
Week 6/ET, Excellent (n=32, 31, 40)375
Week 6/ET, Good (n=32, 31, 40)17919
Week 6/ET, Fair (n=32, 31, 40)657
Week 6/ET, Poor (n=32, 31, 40)6109
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.2473
  • Pregabalin (300 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0239
  • Pregabalin (150 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.6118
  • Pregabalin (300 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.6730
  • Pregabalin (150 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.5954
  • Pregabalin (300 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.7784
  • Pregabalin (150 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.7293
  • Pregabalin (300 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.5202
SecondaryNumber of Subjects With Persistent Pain Based on 11-Point Verbal Rating Scale (VRS)

The presence of persistent pain was evaluated on the 11-point VRS. The subject answered the question: how much pain did you experience in the last 24 hours in your operated knee? A zero score of VRS was the only number considered as a "no." Any positive score (1-10) of VRS was consider as "yes."

Time frame:
Month 3, Month 6 (phone call)
Reported as:
Number · participants
Number of Subjects With Persistent Pain Based on 11-Point Verbal Rating Scale (VRS)
participantsPregabalin (150 mg)Pregabalin (300 mg)Placebo
Month 3, Yes (n=65, 59, 61)222227
Month 3, No (n=65, 59, 61)433734
Month 6, Yes (n=64, 62, 61)191514
Month 6, No (n=64, 62, 61)454747
Statistical analysis
  • Pregabalin (150 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.1509
  • Pregabalin (300 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.3822
  • Pregabalin (150 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.2825
  • Pregabalin (300 mg) vs Placebo · Cochran-Mantel-Haenszel · p = 0.7733
SecondaryNeuropathic Pain Symptom Inventory (NPSI)

NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.

Time frame:
Month 3, Month 6 (phone call)
Reported as:
Mean · scores on a scale
Neuropathic Pain Symptom Inventory (NPSI)
scores on a scalePregabalin (150 mg)Pregabalin (300 mg)Placebo
Burning Spontaneous Pain, Month 3, (n=23, 24, 29)1.348 ± 2.4790.792 ± 2.0850.828 ± 1.947
Burning Spontaneous Pain, Month 6, (n=22, 15, 15)1.091 ± 2.1141.400 ± 2.3240.667 ± 1.113
Pressing Spontaneous Pain, Month 3, (n=23, 24, 29)1.457 ± 2.0830.958 ± 1.5740.948 ± 1.496
Pressing Spontaneous Pain, Month 6, (n=22, 15, 15)1.409 ± 2.1581.333 ± 1.6550.633 ± 1.445
Paroxysmal Pain, Month 3, (n=23, 24, 29)0.804 ± 1.0421.688 ± 2.4171.086 ± 1.909
Paroxysmal Pain, Month 6, (n=22, 15, 15)1.205 ± 2.7111.133 ± 2.1750.533 ± 1.246
Evoked Pain, Month 3, (n=23, 24, 29)1.174 ± 1.7001.319 ± 2.0040.931 ± 1.344
Evoked Pain, Month 6, (n=22, 15, 15)0.636 ± 0.9371.667 ± 2.4020.711 ± 1.298
Paresthesia/Dysesthesia, Month 3, (n=23, 24, 29)0.848 ± 1.4730.604 ± 1.4060.690 ± 1.160
Paresthesia/Dysesthesia, Month 6, (n=22, 15, 15)0.773 ± 1.6740.500 ± 1.0860.033 ± 0.129
Total Score, Month 3, (n=23, 24, 29)0.058 ± 0.0610.055 ± 0.0750.045 ± 0.059
Total Score, Month 6, (n=22, 15, 15)0.051 ± 0.0740.061 ± 0.0780.027 ± 0.036

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin (150 mg)—11/98 (11.2%)76/98 (77.6%)
Pregabalin (300 mg)—11/96 (11.5%)76/96 (79.2%)
Placebo—5/98 (5.1%)81/98 (82.7%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPregabalin (150 mg)Pregabalin (300 mg)Placebo
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/983/960/98
Deep vein thrombosisVascular disorders0/982/960/98
FallInjury, poisoning and procedural complications2/980/960/98
Cardiac failure congestiveCardiac disorders0/981/960/98
Porcelain gallbladderHepatobiliary disorders0/981/960/98
Anaphylactic reactionImmune system disorders0/981/960/98
HaemarthrosisMusculoskeletal and connective tissue disorders0/981/960/98
Joint range of motion decreasedMusculoskeletal and connective tissue disorders1/981/960/98
DepressionPsychiatric disorders0/981/960/98
HypotensionVascular disorders1/981/960/98
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPregabalin (150 mg)Pregabalin (300 mg)Placebo
NauseaGastrointestinal disorders29/9831/9651/98
ConstipationGastrointestinal disorders24/9812/9630/98
DizzinessNervous system disorders20/9825/9616/98
VomitingGastrointestinal disorders14/9815/9625/98
SomnolenceNervous system disorders24/9822/9620/98
PruritusSkin and subcutaneous tissue disorders15/9812/9621/98
FatigueGeneral disorders20/9815/9619/98
InsomniaPsychiatric disorders8/9812/9617/98
PyrexiaGeneral disorders13/9816/965/98
HypotensionVascular disorders12/9811/965/98

Baseline characteristics

Age, Customized
Age, Customized(participants)Pregabalin (150 mg)Pregabalin (300 mg)PlaceboTotal
18 to 44 years1247
45 to 64 years524449145
> = 65 years455045140
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin (150 mg)Pregabalin (300 mg)PlaceboTotal
Female606154175
Male383544117
08

Study locations

27 sites
  • Pfizer Investigational Site
    Northport, Alabama 35476, United States
  • Pfizer Investigational Site
    Tuscaloosa, Alabama 35401, United States
  • Pfizer Investigational Site
    Tuscaloosa, Alabama 35406, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Miami, Florida 331036, United States
  • Pfizer Investigational Site
    Vero Beach, Florida 32960, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Galesburg, Illinois 61401, United States
  • Pfizer Investigational Site
    Lafayette, Louisiana 70503, United States
  • Pfizer Investigational Site
    New Iberia, Louisiana 70563, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21218, United States
  • Pfizer Investigational Site
    Egg Harbor Township, New Jersey 08234, United States
  • Pfizer Investigational Site
    Pomona, New Jersey 08205, United States
  • Pfizer Investigational Site
    Voorhees, New Jersey 08043, United States
  • Pfizer Investigational Site
    New York, New York 10021, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28207, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43214, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43215, United States
  • Pfizer Investigational Site
    Upper Arlington, Ohio 43220, United States
  • Pfizer Investigational Site
    Allentown, Pennsylvania 18103, United States
  • Pfizer Investigational Site
    King Of Prussia, Pennsylvania 19406, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213-2582, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • Pfizer Investigational Site
    Dallas, Texas 75390, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015. PubMed 25565885 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2007
First posted
Mar 2, 2007
Start
May 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Aug 18, 2010
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00442546
Responsible party
Sponsor
First posted
Mar 2, 2007
Start date
May 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Aug 18, 2010
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion